REG - Nuformix PLC - Patent Update

NuformixAnnouncement

17/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240617:nRSQ5819Sa&default-theme=true

RNS Number : 5819S  Nuformix PLC  17 June 2024

17 June 2024

 

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Patent Update

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce the following patent update:

NXP002

NXP002 is the Company's lead asset and a potential novel inhaled treatment for
Idiopathic Pulmonary Fibrosis ("IPF") for which the Company holds multiple
patents:

·    NXP002 Substance of Matter: Following grants in the US and Japan, the
European Patent Office formally issued a grant of patent number 3837238 on 12
June 2024 covering the Company's proprietary NXP002 drug forms being
progressed by the Company as a potential novel IPF treatment.

·    NXP002 Method of Use: The US PTO issued a grant of patent application
17/365,490 on 14 June 2024, covering use of the Company's proprietary drug
forms in the treatment of various diseases including fibrotic lung diseases.

·    NXP002 Compositions for Treatment: Now in national filing stages and
proceeding through examination.

NXP004

The Company's NXP004 programme is focused on the development of novel,
proprietary, cocrystal forms of olaparib, a drug currently marketed by
AstraZeneca, under the Lynparza® brand name. On 14 June 2024 the US Patent
and Trademark Office ("PTO") has granted the Company patent number 12012386
covering the lead cocrystals under development, representing the first granted
patent in this second NXP004 cocrystal series.

Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we've
received these multiple grants of key patents underpinning both our NXP002 and
NXP004 programmes. The European patent grant represents the last major
territory to confirm protection of the novel drug forms enabling NXP002's
development as a potential novel IPF treatment. Granting of the method of use
patent in the US further strengthens our IP position for this programme. The
US PTO's decision to grant the patent protecting the NXP004 programme's lead
cocrystals is also a first, with other territories soon to follow. The
granting of these patents is very helpful and timely in progressing on-going
discussions with potential development partners."

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 Bob Pountney (Corporate Broking)                  +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQZLFFZQLXBBL